Integrin αvβ3 is a
cell adhesion molecule involved in the progression and invasion of
glioblastoma, making it an attractive target for the diagnosis of
glioblastoma. Although some
integrin αvβ3 specific
ligands, such as RGD and its mimetic
peptides (
Cilengitide), have been devoted in detecting
glioblastoma, their clinical practices have been limited due to low specificity and affinity. Herein, we have identified a linear
peptide RWrNK, containing an unnatural d-
arginine (r), as the
integrin αvβ3-specific
ligand. RWrNK shows high binding affinity to
integrin αvβ3 with a Kd value of 1.6 nM, which is 2-fold higher than
Cilengitide (3.2 nM), a well-established
integrin αvβ3
ligand. In addition, RWrNK can not only rapidly transport in human
glioblastoma U87MG cells but effectively label U87MG
tumor spheroids, compared to
Cilengitide, indicating that it possesses an ability to sensitively detect
glioblastoma. Importantly, RWrNK can pass through blood-
brain tumor barrier (BBTB) and selectively accumulate in orthotopic U87MG
tumor within 2 h, allowing for imaging
glioblastoma in vivo with high sensitivity and specificity. Overall, RWrNK has the great potential in
theranostic applications for
glioblastoma, in consideration of its high specificity and affinity for
integrin αvβ3.